InsidersTradesSigma
Track the Helius Medical Technologies, INC. share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Helius Medical Technologies, INC. has logged 32 public disclosures. Market capitalisation: €103.3m. The latest transaction was filed on 15 February 2024 (Acquisition). Among the most active insiders: ANDREEFF DANE. All data is accessible without an account.
32
Insider Decl.
n/a
Thresholds
€423,700
16 ops.
Buy Volume
n/a
n/a
Sell Volume
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,805 of 29,063 companies
26.5
score / 100
Value5
Quality48
FCF yld-58%
Earn yld-39%
EV/EBITDA·
ROE-137%
Gross mgn92%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 February 2024
Declarations32 total
641 shares@ US$6.37040.5% of flowCommon StockSEC:0001140361-24-008177:0
Canonical exit: 28 Feb 2024 (T+90)
2,827 shares@ US$8.0952.8% of flowCommon StockSEC:0001140361-23-057794:0
Canonical exit: 13 Mar 2024 (T+90)
1,131 shares@ US$6.37040.9% of flowCommon StockSEC:0001140361-23-055933:0
Canonical exit: 28 Feb 2024 (T+90)
2,688 shares@ US$6.36842.1% of flowCommon StockSEC:0001140361-23-041885:0
Canonical exit: 26 Nov 2023 (T+90)
83,054 shares0Class A Common StockSEC:0001140361-23-026969:0
83,054 shares0Class A Common StockSEC:0001140361-23-026970:0
83,054 shares0Class A Common StockSEC:0001140361-23-026971:0
83,054 shares0Class A Common StockSEC:0001140361-23-026972:0
43,266 shares@ US$0.24921.4% of flowCommon StockSEC:0001140361-22-046037:0
Canonical exit: 16 Mar 2023 (T+90)
10,300 shares@ US$0.28340.4% of flowCommon StockSEC:0001140361-22-043128:0
Canonical exit: 20 Feb 2023 (T+90)
10,000 shares@ US$0.28340.4% of flowCommon StockSEC:0001140361-22-042922:0
Canonical exit: 20 Feb 2023 (T+90)
10,000 shares@ US$0.32240.4% of flowCommon StockSEC:0001140361-22-042310:0
Canonical exit: 14 Feb 2023 (T+90)
4,752 shares@ US$0.54440.3% of flowCommon StockSEC:0001104659-22-100051:0
Canonical exit: 11 Dec 2022 (T+90)
13,503 shares@ US$0.64991.2% of flowCommon StockSEC:0001140361-22-031005:0
Canonical exit: 22 Nov 2022 (T+90)
6,049 shares0Class A Common StockSEC:0001140361-22-020591:0
6,049 shares0Class A Common StockSEC:0001140361-22-020589:0
6,049 shares0Class A Common StockSEC:0001140361-22-020594:0
6,049 shares0Class A Common StockSEC:0001140361-22-020582:0
8,011 shares0Class A Common StockSEC:0001209191-22-011221:0
1,275 shares@ US$5.25280.0047% mcap0.9% of flowClass A Common StockSEC:0001209191-21-070723:0
Canonical exit: 17 Mar 2022 (T+90)
3,000 shares@ US$5.30980.011% mcap50.0% of flowClass A Common StockSEC:0001209191-21-070472:0
Canonical exit: 17 Mar 2022 (T+90)
22,960 shares@ US$8.000.13% mcap24.1% of flowCommon StockSEC:0001209191-21-064379:0
Canonical exit: 10 Feb 2022 (T+90)
5,408 shares@ US$14.722216.4% of flowCommon StockSEC:0001209191-21-056384:0
Canonical exit: 14 Dec 2021 (T+90)
721 shares0Class A Common StockSEC:0001209191-21-055888:0
5,408 shares@ US$14.962916.7% of flowCommon StockSEC:0001209191-21-055662:0
Canonical exit: 9 Dec 2021 (T+90)
25 of 32 declarations
关于 Helius Medical Technologies, INC.
HELIUS MEDICAL TECHNOLOGIES, INC.（股票代码：HSDT）是一家在美国上市的公司，曾在纳斯达克市场交易。历史上，Helius 是一家高度专业化的神经技术和医疗设备公司，专注于非植入式神经调节解决方案，旨在帮助患有神经功能缺陷（尤其是平衡和步态障碍）的患者。其主要行政办公室位于美国宾夕法尼亚州纽敦，这突显了其在美国的运营基地以及其作为利基医疗技术公司而非多元化医疗保健平台的身份。 该公司成立于 2014 年，当时它完成了对 NeuroHabilitation Corporation 的收购，并采用了 Helius Medical Technologies 的名称，以反映其新的战略方向。随着时间的推移，Helius 围绕一个单一的主要平台开展业务：便携式神经调节刺激器 (PoNS)。PoNS 是一种可穿戴设备，由控制器和口腔部件组成，可向舌头提供轻微的电刺激。其治疗前提是增强神经可塑性并支持康复锻炼，目标是改善某些神经系统疾病患者的步态和平衡。 实际上，Helius 的核心业务一直围绕 PoNS 疗法，并致力于应对将新颖的神经刺激概念转化为商业上可行的产品所需的临床、报销和监管途径。其商业重点是多发性硬化症患者以及与轻度至中度创伤性脑损伤相关的平衡缺陷。因此，该公司的竞争地位是一家小型、差异化的医疗技术创新者：它不是一家广泛的设备制造商，而是一家专注于开发的开发商，其成功取决于临床采用、支付方覆盖和监管进展。 从地理上看，Helius 主要针对美国市场，同时也在加拿大和其他可能扩大可寻址机会的司法管辖区寻求国际影响力。对于法语区欧洲的投资者而言，该名称应被视为一家小型医疗保健公司，具有巨大的执行风险，并可能对报销进展、商业化里程碑和资产负债表管理高度敏感。 最近的发展尤为重要。2025 年，该公司报告了融资活动、其商业和报销策略的更新，以及其 PoNS 项目的持续工作。美国证券交易委员会的文件还显示了一项重大的公司转型：2025 年 9 月，Helius 将公司名称更改为 Solana Company，这标志着其战略从最初的医疗技术身份转型。即便如此，Helius 的传统特许经营权仍然由其神经技术起源、其 PoNS 平台以及其尝试开发一种具有临床意义的非侵入性神经康复疗法所定义。
